Key Points
- Executive sale: EVP Shannon Parisotto sold 2,039 Charles River Laboratories shares for approximately $599,711 under a pre-arranged Rule 10b5-1 plan, reducing her direct ownership by 29.78% to 4,807 shares.
- Strong recent performance: CRL opened at $292.97, near its 52-week high of $299.32. The company exceeded quarterly earnings expectations with $3.02 EPS versus $2.77 forecast and generated $1 billion in revenue, though revenue declined 2.7% year over year.
- Analyst outlook remains favorable: Analysts have an overall “Moderate Buy” rating, with 12 Buy, three Hold, and one Sell recommendation; the average price target is $255.65, while Morgan Stanley and TD Cowen recently raised their targets to $300.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) Director Nancy Andrews sold 573 shares of the company's stock in a transaction that occurred on Tuesday, August 18th. The stock was sold at an average price of $285.24, for a total value of $163,442.52. Following the completion of the sale, the director owned 1,438 shares of the company's stock, valued at $410,175.12. This trade represents a 28.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Charles River Laboratories International Stock Up 1.0%
Shares of CRL stock opened at $292.97 on Friday. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $299.32. The stock has a market cap of $13.99 billion, a PE ratio of -60.41, a price-to-earnings-growth ratio of 3.00 and a beta of 1.38. The business's fifty day moving average is $232.83 and its 200-day moving average is $193.15. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 EPS for the quarter, topping analysts' consensus estimates of $2.77 by $0.25. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $980.53 million. Charles River Laboratories International had a positive return on equity of 15.75% and a negative net margin of 5.96%.The company's quarterly revenue was down 2.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current fiscal year.
Institutional Trading of Charles River Laboratories International
Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp increased its stake in Charles River Laboratories International by 167.6% in the 1st quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company's stock valued at $253,000 after buying an additional 1,074 shares during the period. Empowered Funds LLC acquired a new stake in shares of Charles River Laboratories International during the 1st quarter valued at $418,000. American Century Companies Inc. boosted its stake in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company's stock valued at $830,000 after buying an additional 1,616 shares during the period. Brown Advisory Inc. grew its holdings in shares of Charles River Laboratories International by 5.1% during the 2nd quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company's stock valued at $354,000 after acquiring an additional 114 shares in the last quarter. Finally, California Public Employees Retirement System increased its stake in shares of Charles River Laboratories International by 3.9% in the second quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company's stock worth $12,837,000 after acquiring an additional 3,198 shares during the last quarter. 98.91% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Several brokerages have recently issued reports on CRL. Piper Sandler set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Monday, August 10th. JPMorgan Chase & Co. raised shares of Charles River Laboratories International from a "neutral" rating to an "overweight" rating and increased their target price for the company from $180.00 to $310.00 in a research note on Thursday, August 6th. Citigroup restated a "buy" rating on shares of Charles River Laboratories International in a report on Wednesday, July 8th. CLSA lowered shares of Charles River Laboratories International from an "outperform" rating to a "hold" rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. Finally, Royal Bank Of Canada raised their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the stock an "outperform" rating in a research note on Thursday, August 6th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has a consensus rating of "Moderate Buy" and an average target price of $255.65.
Check Out Our Latest Report on Charles River Laboratories International
Charles River Laboratories International Company Profile
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
